help button home button Endocrine Society Molecular Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on October 14, 2004
Molecular Endocrinology, doi:10.1210/me.2004-0215
A more recent version of this article appeared on February 1, 2005
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
19/2/527    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xu, J.
Right arrow Articles by Hershman, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xu, J.
Right arrow Articles by Hershman, J. M.

Submitted on May 27, 2004
Accepted on October 5, 2004

Activation of Nicotinamide N-methyltransferase Gene Promoter by Hepatocyte Nuclear Factor-1{beta} in Human Papillary Thyroid Cancer Cells

Jimin Xu, Marco Capezzone, Xiao Xu, and Jerome M. Hershman*

Endocrinology and Diabetes Division, VA Medical Center, UCLA School of Medicine, Los Angeles, CA

* To whom correspondence should be addressed. E-mail: jhershmn{at}ucla.edu.

We previously demonstrated that the human nicotinamide N-methytransferase (NNMT) gene was highly expressed in many papillary thyroid cancers and cell lines. The expression in other papillary and follicular cancers or cell lines and normal thyroid cells was low or undetectable. To gain an understanding of the molecular mechanism of this cell-specific expression, the NNMT promoter was cloned and studied by luciferase reporter gene assay. The promoter construct was expressed highly in papillary cancer cell lines including those with higher (e.g. BHP 2-7) and lower (e.g. BHP 14-9) NNMT gene expression, and expressed weakly in follicular thyroid cancer cell lines. Further study with 5' deletion promoter construct suggested that the NNMT promoter was regulated differently in BHP 2-7 and BHP 14-9 cells. In BHP 2-7 cells, promoter activity was dependent on an upstream sequence. In BHP 14-9 cells, sequence in the basal promoter region contributed notably to the overall promoter activity. RT-PCR or Western blot analysis indicated that hepatocyte nuclear factor-1 beta (HNF-1{beta}) was expressed in only papillary cancer cell lines with high NNMT gene expression. HNF-1{beta} was not expressed or expressed very weakly in other papillary, follicular and Hurthle cancer cell lines and primary cultures of normal thyroid cells and benign thyroid conditions. A HNF-1 binding site was identified in the NNMT basal promoter region. Mutations in this site decreased NNMT promoter activity in the HNF-1{beta} positive BHP 2-7 cells, but not in the HNF-1{beta} negative BHP 14-9 cells. HNF-1{beta} bound to the HNF-1 site specifically as a homodimer as determined by gel retardation assays with HNF-1{beta} specific antibody. Co-transfection of a HNF-1{beta} expression plasmid increased NNMT promoter activity significantly in both HNF-1{beta} positive and negative thyroid cancer cell lines and Hep G2 liver cancer cells. Furthermore, transient expression of HNF-1{beta} in BHP 14-9 cells increased endogenous NNMT protein level. In summary, HNF-1{beta} functions as a transcription activator for NNMT gene expression in some papillary thyroid cancer cells.


Key words: NNMT • gene regulation • papillary thyroid cancer • HNF-1{beta} • transcription factor







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2004 by The Endocrine Society